Abstract

Current chemotherapies against trypanosomiasis are beset with diverse challenges, a situation which underscores the numerous research efforts aimed at finding newer and effective treatments. Arginine kinase of trypanosome has been validated as target for drug development against trypanosomiasis. The present study investigated the interaction between a recombinant form of the arginine kinase (rTbAK) of trypanosome and gallotannin. The interaction between gallotannin and recombinant arginine kinase of Trypanosoma brucei caused significant decrease of enzyme activity. Kinetic analysis revealed the interaction to be of noncompetitive inhibition. Further thermodynamic analysis showed that the interaction between gallotannin and the recombinant arginine kinase was nonspontaneous and involved hydrophobic forces. The K sv values and the FRET analysis suggest that static quenching of fluorescence intensity by gallotannin was static. Data revealed inhibitory interactions between gallotannin and rTbAK of trypanosome. Although the mechanism of inhibition is not clear yet, molecular docking studies are ongoing to clearly define the inhibitory interactions between the gallotannin and rTbAK. The knowledge of such binding properties would enrich development of selective inhibitors for the arginine kinase of Trypanosoma brucei.

Highlights

  • African trypanosomiasis is one of the neglected diseases currently ravaging several countries in the sub-Saharan Africa

  • The interaction of various concentrations of gallotannin resulted in significant decrease in the activity of rTbAK by an approximate >80% relative to the control assay, which lacked the presence of gallotannin (Figures 1 and 2)

  • The kinetic parameters for the interaction of gallotannin with rTbAK were determined by including the gallotannin at a concentration of 10–50 nM with either arginine, between 0.1 and 2 mM concentration at fixed level of ATP (0.5 mM), or ATP, between 0.1 and 0.5 mM concentration at fixed level of arginine (2 mM)

Read more

Summary

Introduction

African trypanosomiasis is one of the neglected diseases currently ravaging several countries in the sub-Saharan Africa. Chemotherapy which forms the major means of controlling the disease scourge is currently faced with many challenges including limited efficacy, unwanted toxicity, and emergence of resistant strain of trypanosomes [1]. These and other factors underscore the research efforts aimed at finding better chemotherapy for trypanosomiasis. Arginine kinase (AK) is a phosphotransferase enzyme, which has been validated as a drug target for selective trypanocide development [2,3,4,5]. AK is absent in humans, making it a choice target for selective inhibition as well as for trypanocide development [10]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call